Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
04 2022
Historique:
received: 04 01 2022
accepted: 05 02 2022
pubmed: 7 4 2022
medline: 14 4 2022
entrez: 6 4 2022
Statut: ppublish

Résumé

No recommendations exist regarding optimal follow-up schedule in patients with eosinophilic esophagitis (EoE) under maintenance treatment. We retrospectively evaluated a long-term surveillance concept at the Swiss EoE clinic, where clinical, endoscopic and histological disease activity is assessed annually regardless of EoE symptoms. Data on 159 adult patients under maintenance steroid treatment with available follow-up were analyzed. Patients were classified as having close (duration between visits <18 months) or non-close follow-up (≥18 months). We analyzed a total of 309 follow-up visits of 159 patients (123 males, age at diagnosis 38.9 ± 15.4 years). 157 (51%) visits were within a close follow-up schedule (median duration between visits of 1.0 years (interquartile range (IQR) 0.9-1.2)), while 152 visits (49%) were not (median duration between visits 2.9 years (IQR 2.0-4.1)). There was no difference regarding ongoing clinical, endoscopic, and histological disease activity, and adherence to prescribed steroid treatment between the two groups. However, stricture formation was significantly less frequently observed at visits within a close follow-up schedule (22.9 vs. 33.6%, p = 0.038). Absence of close follow-up was a significant risk factor for stricture development in a multivariate regression model. Patients who achieved histological remission and were followed within a close-follow-up schedule had significantly earlier detection of histological relapse compared to patients not within such close follow-up. Close follow-up is associated with fewer stricture formation and appears to result in earlier detection of histological relapse in patients with eosinophilic esophagitis. We advocate for regular assessment of disease activity (every 12-18 months) in order to detect relapsing disease as early as possible, and therefore potentially minimize the risk for EoE complications.

Sections du résumé

BACKGROUND AND AIMS
No recommendations exist regarding optimal follow-up schedule in patients with eosinophilic esophagitis (EoE) under maintenance treatment.
METHODS
We retrospectively evaluated a long-term surveillance concept at the Swiss EoE clinic, where clinical, endoscopic and histological disease activity is assessed annually regardless of EoE symptoms. Data on 159 adult patients under maintenance steroid treatment with available follow-up were analyzed. Patients were classified as having close (duration between visits <18 months) or non-close follow-up (≥18 months).
RESULTS
We analyzed a total of 309 follow-up visits of 159 patients (123 males, age at diagnosis 38.9 ± 15.4 years). 157 (51%) visits were within a close follow-up schedule (median duration between visits of 1.0 years (interquartile range (IQR) 0.9-1.2)), while 152 visits (49%) were not (median duration between visits 2.9 years (IQR 2.0-4.1)). There was no difference regarding ongoing clinical, endoscopic, and histological disease activity, and adherence to prescribed steroid treatment between the two groups. However, stricture formation was significantly less frequently observed at visits within a close follow-up schedule (22.9 vs. 33.6%, p = 0.038). Absence of close follow-up was a significant risk factor for stricture development in a multivariate regression model. Patients who achieved histological remission and were followed within a close-follow-up schedule had significantly earlier detection of histological relapse compared to patients not within such close follow-up.
CONCLUSION
Close follow-up is associated with fewer stricture formation and appears to result in earlier detection of histological relapse in patients with eosinophilic esophagitis. We advocate for regular assessment of disease activity (every 12-18 months) in order to detect relapsing disease as early as possible, and therefore potentially minimize the risk for EoE complications.

Identifiants

pubmed: 35384368
doi: 10.1002/ueg2.12216
pmc: PMC9004232
doi:

Substances chimiques

Steroids 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

308-318

Subventions

Organisme : NIH HHS
ID : U54 AI117804 CEGIR training grant
Pays : United States
Organisme : NCATS NIH HHS
ID : U2C TR002818
Pays : United States
Organisme : Swiss National Science Foundation
ID : 32003B_160115
Pays : Switzerland
Organisme : NIAID NIH HHS
ID : U54 AI117804
Pays : United States
Organisme : Swiss National Science Foundation
ID : P2ZHP3_168561
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 32003B_204751/1
Pays : Switzerland

Informations de copyright

© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.

Références

Gut. 2016 Mar;65(3):390-9
pubmed: 25792708
Clin Transl Gastroenterol. 2018 Dec;9(12):e212
pubmed: 30802222
Clin Gastroenterol Hepatol. 2019 Feb;17(3):419-428.e6
pubmed: 29902648
Schweiz Med Wochenschr. 1994 Aug 20;124(33):1419-29
pubmed: 7939509
J Allergy Clin Immunol. 2009 Aug;124(2 Suppl):S35-42
pubmed: 19647134
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2
pubmed: 21477849
Gut. 2013 Apr;62(4):489-95
pubmed: 22619364
Dig Dis Sci. 1993 Jan;38(1):109-16
pubmed: 8420741
Allergy. 2014 Sep;69(9):1248-54
pubmed: 24894658
Gastroenterology. 2010 Aug;139(2):418-29
pubmed: 20457157
Clin Gastroenterol Hepatol. 2011 May;9(5):400-9.e1
pubmed: 21277394
Gastroenterology. 2019 Jul;157(1):74-86.e15
pubmed: 30922997
Gastroenterology. 2013 Dec;145(6):1230-6.e1-2
pubmed: 23954315
United European Gastroenterol J. 2022 Apr;10(3):308-318
pubmed: 35384368
Gastroenterology. 2003 Dec;125(6):1660-9
pubmed: 14724818
Gastroenterology. 2010 Nov;139(5):1526-37, 1537.e1
pubmed: 20682320
Arerugi. 2012 Jul;61(7):959-69
pubmed: 23007333
Clin Gastroenterol Hepatol. 2008 Feb;6(2):165-73
pubmed: 18237866
Gastroenterology. 2020 Nov;159(5):1672-1685.e5
pubmed: 32721437
J Allergy Clin Immunol. 2011 Dec;128(6):1349-1350.e5
pubmed: 22019091
Gastroenterology. 2017 Mar;152(4):776-786.e5
pubmed: 27889574
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2514-2523.e2
pubmed: 32798703
Am J Gastroenterol. 2017 Oct;112(10):1527-1535
pubmed: 28719593

Auteurs

Lorenz Bon (L)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Ekaterina Safroneeva (E)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Christian Bussmann (C)

Pathology Viollier AG, Basel, Switzerland.

Luc Biedermann (L)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Philipp Schreiner (P)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Stephan R Vavricka (SR)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Center for Gastroenterology and Hepatology, Zurich, Switzerland.

Alain M Schoepfer (AM)

Division of Gastroenterology and Hepatology, University Hospital Lausanne - Centre Hopitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Talaya McCright-Gill (T)

Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Hans-Uwe Simon (HU)

Institute of Biochemistry, Medical School Brandenburg, Neuruppin, Germany.
Institute of Pharmacology, University of Bern, Bern, Switzerland.

Alex Straumann (A)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Mirna Chehade (M)

Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Thomas Greuter (T)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Division of Gastroenterology and Hepatology, University Hospital Lausanne - Centre Hopitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH